According to a recent systematic review, the global prevalence of depression in people aged >60 years is estimated to be 28%.1 The relationship of major depressive disorder (MDD) and dementia is complex, with MDD and dementia commonly co-occurring within the ageing population;2,3 approximately 40% of people living with dementia will experience depressive symptoms.4 Currently, there are an estimated 55 million people living with dementia. However, by 2050 this is expected to rise to 139 million.5 An industry mini session held at the 36th ECNP Congress, Barcelona, October 7−10 2023 featuring Professor Nicola Lautenschlager, University of Melbourne, Australia and Professor Luis Agüera Ortiz, Complutense University of Madrid, Spain, asked how we can better identify and manage depression and co-morbid dementia in an ageing population; see the infographic to discover more.6

Educational financial support for this session was provided by H. Lundbeck A/S.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

Job Code: IE-NPDEP-0109 Date of preparation: October 2023

References
  1. Hu T et al. Psychiatry Res 2022;311:114511
  2. Asmer MS et al. J Clin Psychiatry 2018;79:17r11772
  3. Weisenbach SL et al. Curr Psychiatry Rep 2012;14:280-8
  4. Leung DKY et al. Int J Geriatr Psychiatry 2021;36:1330-44
  5. Alzheimer’s Disease International. World Alzheimer Report 2022. Available at: https://www.alzint.org/u/World-Alzheimer-Report-2022.pdf. Accessed October 2023.
  6. How can we better identify and manage depression and co-morbid dementia in an ageing population? Online session at: 36th ECNP Congress; 2023 October 7; Barcelona and virtual.
You are leaving Progress in Mind Ireland
(Non-Promotional Content)
Hello
Please confirm your email
We are sending you a confirmation link to your email address.
In order to get the access, please, check your email and confirm your registration.
The information on this site is exclusively intended for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country